WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives $31.67 Consensus Target Price from Analysts

WAVE Life Sciences Ltd. (NASDAQ:WVE) has earned a consensus rating of “Moderate Buy” from the fourteen research firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and thirteen have assigned a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $31.6667.

WVE has been the topic of several recent research reports. Morgan Stanley set a $28.00 price target on WAVE Life Sciences in a research note on Monday, December 8th. UBS Group set a $32.00 price target on shares of WAVE Life Sciences in a research note on Tuesday, December 16th. Truist Financial lifted their price target on shares of WAVE Life Sciences from $36.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Citigroup upped their price objective on shares of WAVE Life Sciences from $16.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Finally, Canaccord Genuity Group lifted their target price on shares of WAVE Life Sciences from $19.00 to $40.00 and gave the company a “buy” rating in a report on Monday, December 8th.

Insider Buying and Selling at WAVE Life Sciences

In related news, CFO Kyle Moran sold 210,000 shares of the stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $14.77, for a total transaction of $3,101,700.00. Following the sale, the chief financial officer directly owned 89,218 shares of the company’s stock, valued at approximately $1,317,749.86. This represents a 70.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Christian O. Henry sold 93,445 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $14.65, for a total transaction of $1,368,969.25. Following the sale, the director owned 12,700 shares of the company’s stock, valued at approximately $186,055. This represents a 88.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 912,117 shares of company stock valued at $13,464,044 in the last ninety days. Corporate insiders own 23.98% of the company’s stock.

Institutional Trading of WAVE Life Sciences

Institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of WAVE Life Sciences by 9.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,349 shares of the company’s stock valued at $463,000 after purchasing an additional 4,957 shares during the last quarter. Goldman Sachs Group Inc. grew its position in WAVE Life Sciences by 3.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 557,644 shares of the company’s stock worth $4,506,000 after purchasing an additional 20,624 shares during the period. Platinum Investment Management Ltd. raised its stake in WAVE Life Sciences by 13.9% during the 2nd quarter. Platinum Investment Management Ltd. now owns 355,353 shares of the company’s stock valued at $2,310,000 after buying an additional 43,361 shares during the last quarter. TD Asset Management Inc raised its stake in WAVE Life Sciences by 16.3% during the 2nd quarter. TD Asset Management Inc now owns 179,608 shares of the company’s stock valued at $1,167,000 after buying an additional 25,200 shares during the last quarter. Finally, Privium Fund Management B.V. lifted its holdings in shares of WAVE Life Sciences by 19.4% during the 2nd quarter. Privium Fund Management B.V. now owns 135,550 shares of the company’s stock valued at $884,000 after buying an additional 22,000 shares during the period. Hedge funds and other institutional investors own 89.73% of the company’s stock.

WAVE Life Sciences Trading Down 2.5%

Shares of WVE opened at $13.47 on Thursday. WAVE Life Sciences has a 1-year low of $5.28 and a 1-year high of $21.73. The firm’s 50-day moving average price is $13.43 and its 200-day moving average price is $9.90. The firm has a market capitalization of $2.25 billion, a price-to-earnings ratio of -17.96 and a beta of -1.82.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.02). WAVE Life Sciences had a negative net margin of 111.64% and a negative return on equity of 75.61%. The firm had revenue of $7.61 million for the quarter, compared to the consensus estimate of $9.85 million. On average, research analysts forecast that WAVE Life Sciences will post -1.14 EPS for the current fiscal year.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.